No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate

ACC007 is a new-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) with favorable pharmacokinetic and safety profiles. NNRTIs are typically administered in combination with two nucleoside reverse transcriptase inhibitors as first-line recommended regimens in several guidelines. ABSTRACT ACC007 is a new-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) with favorable pharmacokinetic and safety profiles. NNRTIs are typically administered in combination with two nucleoside reverse transcriptase inhibitors as first-line recommended regimens in several guidelines. Therefore, this open-label, randomized, single-period, parallel-cohort study aimed to assess the drug-drug interactions (DDIs) and safety profiles of ACC007 in combination with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) in healthy subjects. All 24 screened subjects were randomly assigned to group A or B. On days 1 to 17, 3TC at 300 mg and TDF at 300 mg were taken orally by group A, and ACC007 at 300 mg was coadministered on days 8 to 17. On days 1 to 17, 300 mg of ACC007 was taken orally by group B, and 300 mg 3TC and 300 mg TDF were coadministered on days 8 to 17. When we compared 3TC-TDF versus 3TC-TDF-ACC007 DDIs, the geometric mean ratios (GMRs, with 90% confidence intervals [CIs] in parentheses) of the maximum concentration at steady state (Cmax,ss) and area under the concentration-time curve from 0 h to infinity (i.e., at steady state; AUCss) values for TDF were 108.14% (95.68 to 122.22%) and 89.90% (82.67 to 97.76%) (P = 0.344); for 3TC, these values were 113.48% (91.45 to 140.82%) and 95.33% (83.61 to 108.7%) (P = 0.629). When ACC007 alone was compared to the combination 3TC-TDF-ACC007, the GMRs (90% CIs) of the Cmax,ss and AUCss values for ACC007 were 89.00% (76.35 to 103.74%) and 82.57% (73.27 to 93.05%) (P = 0.375). The coadministration of 3TC-TDF-ACC007 did not significantly affect the time to maximum concentration of any of the drugs in terms of P values. ACC007 combined with 3TC-TDF was generally well tolerated during daily dosing for 17 days with no serious adverse events. Overall, ACC007 and 3TC-TDF had no significant or meaningful interactions and a favorable safety profile, which supports the use of the combination regimen.

[1]  O. Kirk,et al.  Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021 , 2022, HIV medicine.

[2]  Taisheng Li Chinese Guidelines for the Diagnosis and Treatment of HIV/AIDS (2021 Edition) , 2022, Infectious Diseases & Immunity.

[3]  Eunwoo Kim,et al.  Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects , 2021, Translational and clinical pharmacology.

[4]  Yong-tang Zheng,et al.  The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro. , 2020, Current HIV research.

[5]  W. Kraft,et al.  No Meaningful Drug Interactions with Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate Coadministration , 2019, Antiviral therapy.

[6]  Murali M. Yallapu,et al.  Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment , 2019, Expert opinion on drug metabolism & toxicology.

[7]  C. Fichtenbaum,et al.  Emerging reverse transcriptase inhibitors for HIV-1 infection , 2018, Expert opinion on emerging drugs.

[8]  T. Cihlar,et al.  Current status and prospects of HIV treatment. , 2016, Current opinion in virology.

[9]  Joo-Youn Cho,et al.  Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects , 2014, Drug design, development and therapy.

[10]  Jason J Schafer,et al.  Rilpivirine, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor for the Management of HIV-1 Infection: A Systematic Review , 2012, Antiviral therapy.

[11]  Graham Patrick Drug Metabolism , 2007, Definitions.

[12]  J. Gallant The Ideal Nucleoside/Nucleotide Backbone , 2004, Journal of acquired immune deficiency syndromes.

[13]  G. E. Pakes,et al.  Clinical Pharmacokinetics of Lamivudine , 1999, Clinical pharmacokinetics.